Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has received clearance from the U.S. Food and Drug Administration (FDA) to advance its lead multiple sclerosis (MS) candidate, Lucid-MS (Lucid-21-302), into Phase 2 clinical development. The approval of the Investigational New Drug (IND) application marks a significant milestone for the company, as it moves forward with a therapy that aims to address the underlying neurodegeneration of MS rather than merely managing immune response.
Lucid-MS is designed to provide neuroprotection by inhibiting demyelination, the process by which the protective myelin sheath around nerve fibers is damaged. This mechanism differentiates it from existing MS therapies, which primarily modulate the immune system. The candidate targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation, and has demonstrated the ability to prevent and reverse myelin breakdown in preclinical models.
The planned Phase 2 study will be a randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological measures. Trial start-up activities, including site selection, are already underway, with patient enrollment and drug administration expected to begin as quickly as possible.
Prior Phase 1 trials in healthy participants showed that Lucid-MS was well tolerated, with a favorable safety profile. These results, combined with the promising preclinical data, have positioned the compound as a potential first-in-class therapy for MS.
Quantum BioPharma reported having more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, which may help fund the upcoming trial. The company is focused on building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, through its wholly owned subsidiary, Lucid Psycheceuticals Inc.
The FDA's clearance for Lucid-MS is a critical step forward for Quantum BioPharma, as it advances a therapy that could potentially change the treatment landscape for MS, a disease affecting millions worldwide. The company's approach to target demyelination directly offers a new avenue for intervention, potentially slowing or even reversing disability progression.
For more details on the announcement, visit the full press release. Investors and stakeholders can find the latest updates on QNTM in the company's newsroom at https://ibn.fm/QNTM.
